SOURCE: Chimera Biotec

May 22, 2007 17:02 ET

Chimera Biotec Invites Scientists to the Second Imperacer™ Contest

DORTMUND, GERMANY -- (MARKET WIRE) -- May 22, 2007 -- Chimera Biotec GmbH invites scientists in the life sciences to participate in the 2007 Application Contest for ultra sensitive Imperacer™ immunoassays as advancement for ELISA. The first prize is a free feasibility study for the submitted application on Chimera Biotec's Immuno-PCR platform Imperacer™.

Immuno PCR is an upcoming sensitive biomarker detection technology focused on the analysis of low abundant and hardly detectable targets. Fields of application are, for instance, R&D, drug discovery, immunogenicity, monitoring and a broad range of indications like CNS disorders (Alzheimer's disease), cardiovascular and infectious diseases, inflammation (cytokine detection), doping control.

The Immuno PCR combines the advantages of flexible and robust immunoassays with the exponential signal amplification typical for PCR. Using Immuno PCR typically results in a 100-10,000-fold increase in sensitivity compared to standard immunoassays. Moreover, Immuno PCR reveals a very broad linear dynamic range of up to five orders of magnitude. Additional advantages of Immuno PCR include minimized sample volume requirements, high tolerances against drug and matrix effects and its adaptability for the detection of basically any antigen.

Dr. Rohan de Silva is the winner of the 2006 contest for his study on such neurological disorders as Alzheimer's disease. He remarked: "This study could potentially help in differentiating diagnoses and prognoses of related dementias, including Alzheimer's disease and parkinsonian movement disorders, at earlier stages. Thanks to Imperacer's high degree of sensitivity, it should be easier to examine the variants in the TAU protein."

The participants in the contest should seek for solutions for today's scientific challenges demanding the ultra sensitive Chimera Imperacer™ technology.

Interested scientists are invited to participate online before October 2007.

About Chimera Biotec GmbH:

Chimera Biotec GmbH develops and markets ultra sensitive immunoassays based on the company's proprietary Imperacer™ technology. Founded in 2000, the company customizes assays for a variety of applications such as sensitive biomarker detection, kinetics, diagnostics, agriculture and cosmetics industries. Being the only provider of immunoassays that are 100-10,000-fold higher in sensitivity than conventional ELISA, Chimera Biotec focuses on ambitious analytics like pharmaco- and toxicokinetics, Inflammation (cytokine detection), quality assurance, doping testing and ultra sensitive detection of CNS markers (Alzheimer's disease). For further information, please visit the corporate website at:

Contact Information

  • Contact Information:
    Chimera Biotec GmbH
    Emil-Figge-Str. 76a
    44227 Dortmund
    Joachim Dyck
    Email Contact
    Phone +49-30-30112711